Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service mechanical circulatory support cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (146 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 168 | 18% |
| 2020 | 2 | 164 | 22% |
| 2021 | 1 | 142 |
Percutaneous ventricular assist and intra-aortic balloon pump. Professional codes (what the surgeon bills): CPT 33990, 33991, 33995, 33967, 33970; the hospital bills MS-DRG 268, 269.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Coronary intervention (PCI) | 31 | 1,417−6.6%/yr | −6.6%/yr | 4.80.8× | 2% | 1,490 in 2030+0.8%/yr |
| Structural heart (TAVR, TEER) |
Mechanical circulatory support in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Illinois
| ≈ 310 |
| – |
| 2026 est. | ≈ 330 | – |
| 27% |
| 2022 | 0 | 122 | 31% |
| 2023 | 0 | 134 | 35% |
| 2024 | 0 | 154 | 37% |
| 2025 from claims | – | 308 249–362 | 37% |
| 2026 forecast | – | 335 262–420 | 37% |
| 2027 forecast | – | 362 268–478 | 37% |
| 2028 forecast | – | 391 276–539 | 38% |
| 2029 forecast | – | 422 287–605 | 38% |
| 2030 forecast | – | 456 298–676 | 38% |
In 2025, 100% inpatient hospital.
| 698−2.7%/yr |
| −2.7%/yr |
| 0.6 |
| 0% |
| 770 in 2030+1.6%/yr |
| Michigan | 1 | 533−7.6%/yr | −7.6%/yr | 0.6 | 0% | 590 in 2030+1.8%/yr |
| Missouri | 2 | 453−5.2%/yr | −5.2%/yr | 0.7 | 0% | 390 in 2030−2.4%/yr |
| Indiana | 0 | 434−5.5%/yr | −5.5%/yr | 0.6 | 0% | 370 in 2030−2.6%/yr |
| Minnesota | 1 | 304−3.4%/yr | −3.4%/yr | 0.7 | 0% | 490 in 2030+8.1%/yr |
| Wisconsin | 0 | 301−5.6%/yr | −5.6%/yr | 0.5 | 0% | 300 in 2030−0.3%/yr |
| Iowa | 1 | 200−9.7%/yr | −9.7%/yr | 0.5 | 0% | 130 in 2030−7%/yr |
| Kansas | 1 | 186+0.2%/yr | +0.2%/yr | 0.5 | 0% | 360 in 2030+11%/yr |
| 26 |
| 451+5.5%/yr |
| +5.5%/yr |
| 1.50.9× |
| 0% |
| 490 in 2030+1.4%/yr |
No metro breakdown yet.
No company payments named for these products in Nebraska in 2025.
FDA, last 12 months: 48 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.